Abbott (NYSE:ABT) owned Thoratec is seeking approval for a $11.9 million deal to settle class action claims that it and some of its officers hid facts about its Heartmate II heart pump’s thrombosis rate that would have negatively affected share prices, according to recently released court documents. Investor Bradley Cooper originally brought the suit against the company […]
Study: Procedures with Abbott’s Mitraclip show sustained low complication, mortality rates
Despite an increase in the number of procedures due to aging patients, minimally invasive mitral valve repair procedures using Abbott‘s (NYSE:ABT) Mitraclip system maintain a low mortality and complication rate, according to a new study from Mainz University Medical Center’s Center for Cardiology. Researchers in the Germany-based study examined more than 13,575 minimally invasive mitral […]
Abbott again escapes payer’s lawsuit over St. Jude Medical CRM batteries
The Medical Device Amendment’s pre-emption clause continues to provide legal cover for medtech companies in the U.S., with Abbott getting a payer’s lawsuit dismissed over the past week. Abbott faced a purported class-action lawsuit that a third-party payer — the ASEA/AFSCME Local 52 Health Benefits Trust in Alaska — filed last year in federal court in […]
Abbott misses Wall Street expectations on Q4 sales
Abbott (NYSE:ABT) stock is down about 2% today after its fourth-quarter sales failed to meet analyst expectations. The Abbott Park, Ill.–based maker of medical device, pharmaceutical, nutrition and diagnostics products brought in about $7.765 billion in revenue in the quarter ended Dec. 31, 2018. The sales were up 2.3% from $7.589 billion earned during the same […]
Abbott touts effective pain management, lower energy use in BurstDR SCS study results
Abbott (NYSE:ABT) late last week released results from a study of its BurstDR spinal cord stimulation technology, touting that it provided as effective pain relief as standard SCS despite providing lower-energy, intermittent stimulation known as “microdosing,” for patients with chronic intractable pain. Results from the BOLD study were presented at the 22nd Annual North American Neuromodulation […]
FDA clears Abbott’s TactiCath Sensor Enabled AF contact force ablation cath
Abbott (NYSE:ABT) said today that it won FDA approval for its TactiCath Sensor Enabled contact force ablation catheter intended for use in treating atrial fibrillation. The newly cleared TactiCath SE is intended to provide precise images of the heart overlaid with real-time electrical activity information, the Chicago-area medtech company said. The catheter also features an ergonomic […]
Abbott inks deal to test blood donations in Japan
Abbott (NYSE:ABT) said today that it has been selected by the Japanese Red Cross Society (JRC) to partner in screening the country’s blood donations. The eight-year contract is for the exclusive supply of serological instrumentation, tests, and consumables used for blood and plasma screening. The JRC screens approximately 5 million blood donations each year, helping ensure a […]
Abbott to acquire mitral valve device maker Cephea Valve Tech
Abbott (NYSE:ABT) said today that it plans to acquire mitral heart valve replacement tech developer Cephea Valve Technologies for an undisclosed amount. The Chicago-area healthcare giant backed the Santa Clara, Calif.-based valve company in July 2015 and secured an option to purchase it outright, which it has now chosen to exercise. Cephea is developing mitral valve […]
Neuromodulation: Using the brain’s internal language to relieve pain
When a patient walks into Dr. Jason Yong’s clinic at Brigham & Women‘s Faulkner Hospital complaining of pain, his work has just begun. “Pain is a common symptom and it’s totally generic,” Yong explained to MassDevice. “The other thing that makes it challenging is that it’s so subjective.” After Yong exhausts the pharmaceutical possibilities for […]
Abbott wins FDA approval for Amplatzer Piccolo occluder for neonates
The FDA granted pre-market approval for the Amplatzer Piccolo occluder made by Abbott (NYSE:ABT) to treat a congenital heart defect in neonatal infants as small as two pounds, the company said today. The Chicago-area healthcare giant said Amplatzer Piccolo is a transcatheter, self-expanding, wire mesh device that’s inserted via the aortic or pulmonary artery to close a […]
Bigfoot Biomedical inks insulin deal with Eli Lilly
Bigfoot Biomedical said today that it inked a non-exclusive deal with Eli Lilly (NYSE:LLY) to integrate Eli Lilly’s insulin products into Bigfoot’s investigational insulin delivery devices. The California-based company expects to launch its first two insulin delivery systems – Bigfoot Inject and Bigfoot Loop – in 2020, contingent upon finishing a pivotal trial and landing regulatory approvals. Get […]
- 1
- 2
- 3
- …
- 65
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube